Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Women’s Health Knowledge Hub Advances in Alzheimer’s

Navigating neuroimaging in Alzheimer disease care

PET imaging is playing an increasingly critical role in managing AD, but how can you effectively integrate it into clinical practice? Our expert-led program will empower you with practical strategies and real-world case studies.

This content is intended for healthcare professionals outside of the UK.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports

Open Access 03-04-2025 | Opioids | Review

Reflecting on Cancer Pain as Constant Acute Pain, not Chronic Pain. ‘Known Knowns, Known Unknowns, Unknown Unknowns’

Authors: Dympna Waldron, Kirk Levins, David Murphy, Michael McCarthy, David Gorey, Karen Ryan, Eileen Mannion, Bairbre Mc Nicholas, Doiminic Ó Brannagáin, Leona Reilly, Laura Gaffney, Beth Molony, Mary Healy, Jack Molony, Anthony Dickenson

Published in: Current Oncology Reports

Login to get access

Abstract

Purpose of Review

to explore a paradigm shift in the definition of opioid-responsive cancer pain in this hypothesis-driven review. Opioid-responsive cancer pain may be misplaced within the definition of chronic pain, chronic pain takes three months to establish, early effective control is worthwhile to achieve.

Recent

findings, from a bench-to-bed perspective, debates the interpretation of results supporting the hypothesis that opioid-responsive cancer pain could remain ‘constant acute pain’, with explanations, best solutions, for tolerance and/or addiction, in cancer patients compared to those with chronic pain from other conditions.

Summary

Unraveling the unique apparent properties of opioid-responsive cancer pain empowers knowledge of the process by which acute pain may have the potential to remain acute in nature and not transition into chronic pain. Findings outlined defend the hypothesis of probable sustained acute nature of opioid-responsive cancer pain, importance of early, sustained pain control, opioid reduction and further exploration of this hypothesis in clinical practice.
Literature
1.
2.
Paice JA, et al. AAPT diagnostic criteria for chronic cancer pain conditions. J pain. 2017;18(3):233–46.PubMedCrossRef
3.
World Health O. Cancer pain relief, ed. Geneva: World Health Organization; 1986.
4.
Breivik H, et al. Cancer-related pain: a pan-european survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009;20(8):1420–33.PubMedCrossRef
5.
Bonica JJ, Hoffman JF. The Management of Pain with special emphasis on the Use of Analgesic blocks in diagnosis, prognosis, and Therapy. Anesth Analgesia. 1954;34(5):57–8.
6.
Treede R-D, et al. Chronic pain as a symptom or a disease: the IASP classification of Chronic Pain for the International classification of diseases (ICD-11). Pain. 2019;160(1):19–27.
7.
8.
Müller-Schwefe G, et al. Pain in the cancer patient: different pain characteristics CHANGE pharmacological treatment requirements. Curr Med Res Opin. 2014;30(9):1895–908.PubMedCrossRef
9.
Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes, Pain, vol. 82, no. 3, pp. 263–274, 1999.
10.
Nijs J, et al. Treatment of central sensitization in patients with chronic pain: time for change? Expert Opin Pharmacother. 2019;20(16):1961–70.PubMedCrossRef
11.
Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain, pain, vol. 152, no. 3, pp. S2-S15, 2011.
12.
Nijs J, et al. Nociplastic pain criteria or recognition of central sensitization? Pain phenotyping in the past, present and future. J Clin Med. 2021;10(15):3203.PubMedPubMedCentralCrossRef
13.
Asthana R, et al. Framing of the opioid problem in cancer pain management in Canada. Curr Oncol. 2019;26(3):410–3.CrossRef
14.
Wong S-C, Cheung C-W. Optimization of opioid utility in cancer pain populations. Annals Palliat Med. 2020;9(2):558–70.
15.
Santoni A, Santoni M, Arcuri E. Chronic cancer pain: opioids within tumor microenvironment affect neuroinflammation, tumor and pain evolution, Cancers, vol. 14, no. 9, p. 2253, 2022.
16.
Blalock JE, Smith EM. Conceptual development of the immune system as a sixth sense. Brain Behav Immun. 2007;21(1):23–33.PubMedCrossRef
17.
18.
Luger NM et al. Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer vs. inflammatory pain, Pain, vol. 99, no. 3, pp. 397–406, 2002.
19.
Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain, Cell, vol. 139, no. 2, pp. 267–284, 2009.
20.
Hayes J et al. Methadone prescribed as an analgesic by a specialist palliative medicine team in an acute hospital inpatient setting: retrospective study. BMJ Supportive Palliat Care, 13, no. e3, pp. e839-e842, 2023.
21.
Al Mukhaizeem S, et al. Investigating the effectiveness of oral ketamine on pain, mood and quality of life in treatment resistant chronic pain. Front Pain Res. 2023;4:1268985.CrossRef
22.
Hardy J, et al. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol. 2012;30(29):3611–7.PubMedCrossRef
23.
24.
25.
Elman I, Borsook D. Common brain mechanisms of chronic pain and addiction, Neuron, vol. 89, no. 1, pp. 11–36, 2016.
26.
27.
Ye Y, Xu H, Su X, He X. Role of microRNA in governing synaptic plasticity, Neural plasticity, vol. 2016, 2016.
28.
Møller AR. Neural plasticity and disorders of the nervous system. Cambridge University Press; 2006.
29.
Bartel DP. MicroRNAs: target recognition and regulatory functions, cell, vol. 136, no. 2, pp. 215–233, 2009.
30.
Elramah S, et al. Spinal miRNA-124 regulates synaptopodin and nociception in an animal model of bone cancer pain. Sci Rep. 2017;7(1):1–13.CrossRef
31.
Tracey I, Bushnell MC. How neuroimaging studies have challenged us to rethink: is chronic pain a disease? J pain. 2009;10(11):1113–20.PubMedCrossRef
32.
Volkow ND, Collins FS. The role of science in addressing the opioid crisis. N Engl J Med. 2017;377(4):391–4.PubMedCrossRef
33.
34.
Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manag. 2009;38(3):426–39.CrossRef
35.
Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manag. 1995;10(5):378–84.CrossRef
36.
Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer: Interdisciplinary Int J Am Cancer Soc. 1999;86(9):1856–66.CrossRef
37.
Fine PG, Portenoy RK, Evidence AHEP. Establishing best practices for opioid rotation: conclusions of an expert panel, Journal of pain and symptom management, vol. 38, no. 3, pp. 418–425, 2009.
38.
Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145.PubMedCrossRef
39.
Richebe P, Cahana A, Rivat C. Tolerance and opioid-induced hyperalgesia. Is a divorce imminent? Pain, vol. 153, no. 8, pp. 1547–1548, 2012.
40.
41.
Hanks G. Opioid-responsive and opioid-non-responsive pain in cancer. Br Med Bull. 1991;47(3):718–31.PubMedCrossRef
42.
Mercadante S. Opioid responsiveness in Cancer Pain Management. In: Schmidt RF, Willis WD, editors. Encyclopedia of Pain. Berlin, Heidelberg: Springer Berlin Heidelberg; 2007. pp. 1559–61.CrossRef
43.
Davis MP. Drug management of visceral pain: concepts from basic research, Pain research and treatment, vol. 2012, no. 1, p. 265605, 2012.
44.
45.
Fallon M, et al. Management of cancer pain in adult patients: ESMO Clinical Practice guidelines. Ann Oncol. 2018;29:iv166–91.PubMedCrossRef
46.
Tsang A, et al. Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders. J pain. 2008;9(10):883–91.PubMedCrossRef
47.
48.
Mao J. Challenges of managing chronic pain. Volume 356. ed: British Medical Journal Publishing Group; 2017.
49.
50.
Nijs J, Malfliet A, Nishigami T. Nociplastic pain and central sensitization in patients with chronic pain conditions: a terminology update for clinicians. Braz J Phys Ther, 27, 3, 2023.
51.
Nijs J, et al. Central sensitisation in chronic pain conditions: latest discoveries and their potential for precision medicine. Lancet Rheumatol. 2021;3(5):e383–92.PubMedCrossRef
52.
Martucci KT, Ng P, Mackey S. Neuroimaging chronic pain: what have we learned and where are we going? Future neurology, vol. 9, no. 6, pp. 615–626, 2014.
53.
Zambreanu L, Wise RG, Brooks JC, Iannetti GD, Tracey I. A role for the brainstem in central sensitisation in humans. Evidence from functional magnetic resonance imaging, Pain, vol. 114, no. 3, pp. 397–407, 2005.
54.
Al-Hashimi M, Scott S, Thompson J, Lambert D. Opioids and immune modulation: more questions than answers. Br J Anaesth. 2013;111(1):80–8.PubMedCrossRef
55.
Sacerdote P. Opioids and the immune system, Palliative medicine, vol. 20, no. 8_suppl, pp. 9–15, 2006.
56.
Plein LM, Rittner HL. Opioids and the immune system–friend or foe. Br J Pharmacol. 2018;175(14):2717–25.PubMedCrossRef
57.
Sims-Williams H, et al. Deep brain stimulation of the periaqueductal gray releases endogenous opioids in humans. NeuroImage. 2017;146:833–42.PubMedCrossRef
58.
59.
Banerjee S et al. Morphine induced exacerbation of sepsis is mediated by tempering endotoxin tolerance through modulation of miR-146a, Scientific reports, vol. 3, no. 1, p. 1977, 2013.
60.
Waldron D, Grummell M, Daniels F, Mannion E. A retrospective review to test the hypothesis that opioid toxicity, developing in an otherwise stable patient heralds imminent sepsis. Palliat Med, 22, 2008.
61.
McLymont N, Glover GW. Scoring systems for the characterization of sepsis and associated outcomes. Annals Translational Med, 4, 24, 2016.
62.
Goulden R, et al. qSOFA, SIRS and NEWS for predicting inhospital mortality and ICU admission in emergency admissions treated as sepsis. Emerg Med J. 2018;35(6):345–9.PubMedCrossRef
63.
64.
LeGrand SB. Delirium in palliative medicine: a review. J Pain Symptom Manag. 2012;44(4):583–94.CrossRef
65.
66.
Osman NI, Baghdoyan HA, Lydic R. Morphine inhibits acetylcholine release in rat prefrontal cortex when delivered systemically or by microdialysis to basal forebrain. Anesthesiology: J Am Soc Anesthesiologists. 2005;103(4):779–87.CrossRef
67.
Taylor AM, Becker S, Schweinhardt P, Cahill C. Mesolimbic dopamine signaling in acute and chronic pain: implications for motivation, analgesia, and addiction, Pain, vol. 157, no. 6, p. 1194, 2016.
68.
69.
Ungless MA, Magill PJ, Bolam JP. Uniform inhibition of dopamine neurons in the ventral tegmental area by aversive stimuli. Science. 2004;303(5666):2040–2.PubMedCrossRef
70.
Enna S, McCarson KE. The role of GABA in the mediation and perception of pain. Adv Pharmacol. 2006;54:1–27.PubMedCrossRef
71.
72.
Kearney M. Mortally wounded: Stories of soul pain, death and healing. Marino, 1996.
73.
Gomes-Ferraz CA, Rezende G, Fagundes AA, d. MMR, De Carlo P. Assessment of total pain in people in oncologic palliative care: integrative literature review. Palliat care Social Pract. 16(2022):26323524221125244.CrossRef
74.
75.
McInerney V, Mannion E, Molony MK, Reilly L, Waldron D. An Intervention Using Quality of Life and Symptom Information as a clinical Tool in patients with Advanced Cancer. Int J Innovative Res Med Sci, 4, 08, pp. 517 to 524– 517 to 524, 2019.
76.
Waldron D, O’Boyle CA, Kearney M, Moriarty M, Carney D. Quality-of-life measurement in advanced cancer: assessing the individual. J Clin Oncol. 1999;17(11):3603–11.PubMedCrossRef
77.
78.
Mannion E, Gilmartin J, McInerney V, Molony MK, Basquille ME, Waldron D. Exploring the Innate Human potential for positive adaptation in the Face of Impending Mortality: is there a response shift in subjective quality of life over Time in a group of patients with Lung Cancer receiving Palliative Treatment? Int J Innovative Res Med Sci, 5, 05, pp. 160 to 168– 160 to 168, 2020.
79.
Rees J, Waldron D, O’Boyle C, Ewings P, MacDonagh R. Prospective vs retrospective assessment of lower urinary tract symptoms in patients with advanced prostate cancer: the effect of ‘response shift’. BJU Int. 2003;92(7):703–6.PubMedCrossRef
80.
Vargas-Schaffer G. Is the WHO analgesic ladder still valid? Twenty-four years of experience. Can Fam Physician. 2010;56(6):514–7.PubMedPubMedCentral
81.
Bawor M, et al. Testosterone suppression in opioid users: a systematic review and meta-analysis. Drug Alcohol Depend. 2015;149:1–9.PubMedCrossRef
82.
Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids, Cancer, vol. 100, no. 4, pp. 851–858, 2004.
83.
84.
Chu LF, Dairmont J, Zamora AK, Young CA, Angst MS. The endogenous opioid system is not involved in modulation of opioid-induced hyperalgesia. J Pain. 2011;12(1):108–15.PubMedCrossRef
85.
Sakurada T, et al. Intrathecal high-dose morphine induces spinally-mediated behavioral responses through NMDA receptors. Mol Brain Res. 2002;98:1–2.CrossRef
86.
Loeser JD. Bonica’s Management of Pain 3rd edition. Lippincott Williams & Wilkins Publishers, 2001.
87.
Noordenbos W. Some historical aspects, Pain, vol. 29, no. 2, pp. 141–150, 1987.
88.
Mendell LM. Constructing and deconstructing the gate theory of pain, Pain®, vol. 155, no. 2, pp. 210–216, 2014.
89.
90.
Kumazawa T, Perl E. Excitation of marginal and substantia gelatinosa neurons in the primate spinal cord: indications of their place in dorsal horn functional organization. J Comp Neurol. 1978;177(3):417–34.PubMedCrossRef
91.
92.
Dickenson AH, Editorial I. Gate Control Theory of pain stands the test of time. Oxford University Press; 2002.
93.
94.
Gustafsson M, Silva V, Valeiro C, Joaquim J, van Hunsel F, Matos C. Misuse, Abuse and Medication Errors’ Adverse Events Associated with Opioids—A Systematic Review, Pharmaceuticals, vol. 17, no. 8, p. 1009, 2024.
95.
Ni J, Tang X, Chen L. Medication overdose data analysis: a review of medication error reports in the FDA adverse event reporting system (FAERS). BMC Pharmacol Toxicol. 2023;24(1):41.PubMedPubMedCentralCrossRef
96.
Jones J. Gosport War Memorial Hospital: the report of the Gosport Independent Panel. Report no. HC1084, ed, 2018.
97.
98.
McGreal C. American overdose: The opioid tragedy in three acts. PublicAffairs, 2018.
99.
Keefe PR. Empire of pain: The secret history of the Sackler dynasty. Anchor, 2021.
100.
101.
102.
103.
Hemming K, Eldridge S, Forbes G, Weijer C, Taljaard M. How to design efficient cluster randomised trials, bmj, vol. 358, p. j3064, 2017.
104.
Zhang R, et al. Prescription opioids are associated with higher mortality in patients diagnosed with sepsis: a retrospective cohort study using electronic health records. PLoS ONE. 2018;13(1):e0190362.PubMedPubMedCentralCrossRef
105.
106.
Hughes J. Isolation of an endogenous compound from the brain with pharmacological properties similar to morphine. Brain Res. 1975;88(2):295–308.PubMedCrossRef
107.
Holaday JW, Faden AI. Naloxone reversal of endotoxin hypotension suggests role of endorphins in shock. Nature. 1978;275(5679):450–1.PubMedCrossRef
108.
Bone R, Jacobs E, Wilson F, Hiller F. Naloxone reversal of hypotension: a clinical study. Am Rev Respir Dis. 1982;125:93.
109.
Canady J, Williams W, Thompson I, Vincent GS, Hoover E. Use of naloxone in septic shock. J Natl Med Assoc. 1989;81(6):669.PubMedPubMedCentral
110.
Boeuf B et al. Naloxone for shock, Cochrane Database of Systematic Reviews, vol. 2010, no. 1, 1996.
111.
Sakaryaa M, Sakaryab A, Aydedeb H, Topcua I, Onguna B, Erhanb Y. Can naloxone be a prokinetic agent in sepsis? Clin Intensive Care. 2001;12(2):61–5.CrossRef
112.
Agar MR, et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Intern Med. 2017;177(1):34–42.PubMedCrossRef
113.
Slatkin N, Rhiner M. Treatment of opioid-induced delirium with acetylcholinesterase inhibitors: a case report. J Pain Symptom Manag. 2004;27(3):268–73.CrossRef
114.
Andersen-Ranberg NC, et al. Haloperidol for the treatment of delirium in ICU patients. N Engl J Med. 2022;387(26):2425–35.PubMedCrossRef
115.
Yoo SH, et al. Opioid use and subsequent delirium risk in patients with advanced cancer in palliative care: a multicenter registry study. Sci Rep. 2024;14(1):6004.PubMedPubMedCentralCrossRef
116.
Qi C, et al. Chronic inflammatory pain decreases the glutamate vesicles in presynaptic terminals of the nucleus accumbens. Mol Pain. 2018;14:1744806918781259.PubMedPubMedCentralCrossRef
117.
Huang Y-J, Lee KH, Murphy L, Garraway SM, Grau JW. Acute spinal cord injury (SCI) transforms how GABA affects nociceptive sensitization. Exp Neurol. 2016;285:82–95.PubMedPubMedCentralCrossRef
118.
Vander Weele CM, et al. Rapid dopamine transmission within the nucleus accumbens: dramatic difference between morphine and oxycodone delivery. Eur J Neurosci. 2014;40(7):3041–54.PubMedPubMedCentralCrossRef
119.
Covey DP, Cheer JF. Pick your poison: not all opioids are created equal in the eyes of dopamine (Commentary on Vander Weele. et al) Eur J Neurosci. 2014;40(7):3040.CrossRef
120.
Comer SD, Sullivan MA, Whittington RA, Vosburg SK, Kowalczyk WJ. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers, Neuropsychopharmacology, vol. 33, no. 5, pp. 1179–1191, 2008.
121.
Gaertner J, Boehlke C, Simone CB II, and, Hui D. Early palliative care and the opioid crisis: ten pragmatic steps towards a more rational use of opioids. Annals Palliat Med. 2019;8(4):49097–497.CrossRef
122.
Dalal S, Bruera E. Pain management for patients with advanced cancer in the opioid epidemic era. Am Soc Clin Oncol Educational Book. 2019;39:24–35.PubMedCrossRef
123.
Paice JA, et al. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(27):3325–45.PubMedCrossRef
124.
McGreevy K, Bottros MM, Raja SN. Preventing chronic pain following acute pain: risk factors, preventive strategies, and their efficacy. Eur J pain Supplements. 2011;5(2):365–76.CrossRef
125.
van den Beuken-van MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. High prevalence of pain in patients with cancer in a large population-based study in The Netherlands, Pain, vol. 132, no. 3, pp. 312–320, 2007.
126.
127.
128.
Dahan A, Overdyk F, Smith T, Aarts L, Niesters M. Pharmacovigilance: a review of opioid-induced respiratory depression in chronic pain patients. Pain Physician, 16, 2, pp. E85-94, 2013.
129.
Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology: J Am Soc Anesthesiologists. 2010;112(1):226–38.CrossRef
130.
Dahan A, van der Schrier R, Smith T, Aarts L, van Velzen M, Niesters M. Averting opioid-induced respiratory depression without affecting analgesia. Anesthesiology: J Am Soc Anesthesiologists. 2018;128(5):1027–37.CrossRef
131.
132.
133.
Jackson K, et al. The effectiveness and adverse effects profile of burst ketamine in refractory cancer pain: the VCOG PM 1– 00 study. J Palliat Care. 2010;26(3):176–83.PubMedCrossRef
134.
Langford RM, Knaggs R, Farquhar-Smith P, Dickenson AH. Is tapentadol different from classical opioids? A review of the evidence. Br J pain. 2016;10(4):217–21.PubMedPubMedCentralCrossRef
135.
Mercadante S, et al. Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin. 2012;28(11):1775–9.PubMedCrossRef
136.
137.
Burton AW, et al. Epidural and intrathecal analgesia is effective in treating refractory cancer pain. Pain Med. 2004;5(3):239–47.PubMedCrossRef
138.
Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case–control study. PLoS Med. 2017;14(10):e1002396.PubMedPubMedCentralCrossRef
139.
Davis AM, Inturrisi CE. d-Methadone blocks morphine tolerance andn-methyl-D-aspartate-induced hyperalgesia. J Pharmacol Exp Ther. 1999;289(2):1048–53.PubMedCrossRef
140.
141.
Chino FL, Kamal A, Chino JP. Opioid-associated deaths in patients with cancer: a population study of the opioid epidemic over the past 10 years. American Society of Clinical Oncology; 2018.
142.
Lin C-C, Lai Y-L, Ward SE. Effect of cancer pain on performance status, mood states, and level of hope among Taiwanese cancer patients. J Pain Symptom Manag. 2003;25(1):29–37.CrossRef
143.
Volkow ND, McLellan AT. Opioid abuse in chronic pain—misconceptions and mitigation strategies. N Engl J Med. 2016;374(13):1253–63.PubMedCrossRef
144.
Dalal S, et al. Association between a name change from palliative to supportive care and the timing of patient referrals at a comprehensive cancer center. Oncologist. 2011;16(1):105–11.PubMedPubMedCentralCrossRef
145.
146.
Gawande A. Being mortal: Medicine and what matters in the end. Metropolitan Books; 2014.
Metadata
Title
Reflecting on Cancer Pain as Constant Acute Pain, not Chronic Pain. ‘Known Knowns, Known Unknowns, Unknown Unknowns’
Authors
Dympna Waldron
Kirk Levins
David Murphy
Michael McCarthy
David Gorey
Karen Ryan
Eileen Mannion
Bairbre Mc Nicholas
Doiminic Ó Brannagáin
Leona Reilly
Laura Gaffney
Beth Molony
Mary Healy
Jack Molony
Anthony Dickenson
Publication date
03-04-2025
Publisher
Springer US
Published in
Current Oncology Reports
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-025-01642-w

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more

Incorporating comprehensive genomic profiling into the standard-of-care for NSCLC and thyroid cancer

In this interactive webinar, experts Dr. Subbiah, Dr. Drilon, and Dr. Williams discuss best pathological practices within NSCLC and thyroid cancer, as well as how genomic testing can improve outcomes in clinical practice, using patient case studies as illustrations.

This content is intended only for US-based healthcare providers.

Supported by:
  • Illumina, Inc., and Eli Lilly and Company
Dr. Vivek Subbiah
Dr. Alexander Drilon
Dr. Michelle Williams
Developed by: Springer Healthcare
Watch now
Video

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more
Image Credits